文献速递关节外科

围手术期低剂量奥氮平对全髋关节置换术焦虑患者的显著抗焦虑与加速康复效果:一项随机对照试验

Significant Anxiolytic Effect and Enhanced Recovery Benefits of Perioperative Low-Dose Olanzapine in Patients with Anxiety Undergoing THA: A Randomized Controlled Trial.
PubMed 文献 · J Bone Joint Surg Am · 2026-04-10

该随机对照试验纳入135例术前STAI-S评分≥40分的初次全髋关节置换术患者,随机接受奥氮平2.5mg、阿普唑仑0.4mg或安慰剂每晚口服5天。奥氮平组术后第1、3天STAI-S评分及静息VAS疼痛评分显著低于安慰剂和阿普唑仑组,术后恶心呕吐发生率更低,且阿片类药物消耗更少,髋关节功能恢复更优。

要点

  • 奥氮平组术后第1、3天STAI-S评分显著低于安慰剂和阿普唑仑组。
  • 奥氮平组术后第1至3天静息VAS疼痛评分及阿片类药物消耗显著低于安慰剂组。
  • 奥氮平组术后恶心呕吐发生率显著更低,且Harris髋关节评分和HOOS评分更优。

核心结论

  • 围手术期低剂量奥氮平可能有效降低全髋关节置换术焦虑患者的焦虑水平、改善睡眠障碍、减少术后恶心呕吐、减轻术后疼痛并促进髋关节康复。

研究设计与样本

  • 前瞻性随机对照试验,2024年4月至2025年3月单中心纳入135例拟行初次全髋关节置换术且术前STAI-S评分≥40分的患者。
  • 患者随机接受口服奥氮平2.5mg、阿普唑仑0.4mg或安慰剂,自入院当天起每晚一次,共5天。
  • 奥氮平组45例、阿普唑仑组45例、安慰剂组44例(1例失访)完成术后比较。

主要发现

  • 与安慰剂和阿普唑仑相比,奥氮平组术后第1天和第3天STAI-S评分显著更低。
  • 奥氮平组术后第1至3天静息VAS疼痛评分显著低于安慰剂和阿普唑仑组。
  • 奥氮平组术后恶心呕吐发生率显著更低。
  • 奥氮平组和阿普唑仑组术后第3天PSQI睡眠质量显著优于安慰剂组。
  • 奥氮平组术后第1至3天阿片类药物消耗低于安慰剂组,Harris髋关节评分和HOOS评分更优;三组不良事件无显著差异。

关键数值与推荐

  • 纳入标准为术前STAI-S评分至少40分。
  • 奥氮平剂量为2.5mg,阿普唑仑剂量为0.4mg,每晚一次,共5天。
  • 证据等级为治疗性I级。

临床怎么用

  • 对于术前存在明显焦虑(STAI-S≥40分)的初次全髋关节置换术患者,可考虑围手术期使用低剂量奥氮平2.5mg每晚一次共5天以改善焦虑、疼痛和康复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major anxiety symptoms are commonly observed in patients undergoing total hip arthroplasty (THA); these symptoms exacerbate pain and compromise hip recovery. Olanzapine demonstrates clinically meaningful efficacy in reducing anxiety; thus, we investigated its anxiolytic effect and benefits for enhancing recovery in these high-risk patients. METHODS: We prospectively enrolled 135 patients who were scheduled for primary THA at our institution between April 2024 and March 2025 and who scored at least 40 points on the State-Trait Anxiety Inventory-State (STAI-S) before surgery. Patients randomly received oral olanzapine (2.5 mg), alprazolam (0.4 mg), or a placebo once nightly for 5 days beginning on the day of admission. The 3 groups (45 patients in the olanzapine group, 45 in the alprazolam group, and 44 in the placebo group after 1 patient was lost to follow-up) were compared postoperatively in terms of the STAI-S score, Pittsburgh Sleep Quality Index (PSQI), visual analog scale (VAS) pain score, opioid consumption, and functional recovery of the hip. Adverse events related to drugs and surgery were recorded. RESULTS: Compared with placebo and alprazolam, olanzapine was associated with significantly lower STAI-S scores on postoperative days (PODs) 1 and 3, significantly lower resting VAS pain scores on PODs 1 to 3, and significantly lower incidence of postoperative nausea and vomiting. The olanzapine group and the alprazolam group demonstrated significantly better sleep quality based on the PSQI on POD 3 compared with the placebo group. Moreover, the olanzapine group had lower opioid consumption on PODs 1 to 3 than the placebo group. Patients in the olanzapine group exhibited better Harris hip scores and Hip Disability and Osteoarthritis Outcome Scores. The 3 groups did not significantly differ in terms of adverse events. CONCLUSIONS: Perioperative low-dose olanzapine may be an effective option for reducing anxiety levels, sleep disorders, and postoperative nausea and vomiting, mitigating postoperative pain and enhancing hip recovery among patients with anxiety symptoms undergoing THA. LEVEL OF EVIDENCE: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Jiang B, Fan J, Lai Y, et al. Significant Anxiolytic Effect and Enhanced Recovery Benefits of Perioperative Low-Dose Olanzapine in Patients with Anxiety Undergoing THA: A Randomized Controlled Trial. J Bone Joint Surg Am. 2026. PMID: 41961954. doi:10.2106/JBJS.25.01236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。